UCSF researchers found the cancer drugs letrozole and irinotecan may reverse Alzheimer's effects, reducing tau protein clumps ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

The combination of a recently approved blood test for detection of Alzheimer's disease combined with two medications that ...

Roche is focusing on early diagnosis of Alzheimer's disease and will soon release its first blood-based biomarker for the ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including four-year efficacy and safety data and data on the subcutaneous ...

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation ...

We all forget things. Names, dates, phone chargers – even why we walked into the kitchen. It’s called being human… or, let’s be honest, being over 40 in a digital world with too many tabs open in our ...

Leqembi is the first FDA-approved drug shown to slow the progression of early-stage Alzheimer’s. Medi-Cal can cover Leqembi ...

The Bioindustry Award, now marking its 9th year, recognizes achievements that have significantly contributed to the development of the bioindustry or are expected to contribute to its future growth.

Alzheimer’s Association’s Bike to End ALZ cycling fundraiser across SC from Simpsonville to Charleston finished in Mount ...

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...